We also found that SOX2 gene gain is associated with copy number gains of other actionable oncogenes, including FGFR1 and PIK3CA. Our findings confirm the complexity of NSCLC biology and encourage the exploration of novel therapeutic combinations. This evidence concerns the gene FGFR1 and non-small cell lung carcinoma.